Toxicities of Immunotherapy for Small Cell Lung Cancer
Yang Fu1, Yue Zheng1, Pei-Pei Wang1
1Department of Biotherapy, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Abstract:
Small cell lung cancer (SCLC), composing 15-20% of lung cancer, is a fatal disease with extremely poor prognosis. In the past two decades, etoposide platinum doublet chemotherapy remained the only choice of therapy, with disappointing overall survival ≤1 year for the metastatic disease. Novel treatments including immunotherapy are urgently needed and extensively explored. Recently, in two phase III trials, atezolizumab and durvalumab were shown to bring survival benefit to patients. While immunotherapy brings better outcome, it is accompanied by adverse events different from traditional treatments. Although these immune-related adverse events (irAEs) are generally mild and can be managed, some irAEs (myocarditis, pneumonitis) may be severe and even life-threatening. Accompanying with the increasing application of immunotherapy in clinical practice, the irAEs should not be overlooked. In this review, the irAEs profile in clinical trials of immunotherapy for SCLC will be summarized, also its unique features compared with irAEs in other malignancies will be explored. This review may be helpful for the appropriate clinical use of immunotherapy for SCLC.
Insights
Immunotherapy offers survival benefits for small cell lung cancer (SCLC) patients, but immune-related adverse events (irAEs) like myocarditis and pneumonitis require careful monitoring and management.
Area of Science:
- Oncology
- Pulmonology
- Immunology
Background:
- Small cell lung cancer (SCLC) has a poor prognosis, with limited treatment options and survival rates below one year for metastatic disease.
- Etoposide platinum doublet chemotherapy has been the standard, but novel treatments are crucial.
- Immunotherapy has emerged as a promising therapeutic strategy for SCLC.
Purpose of the Study:
- To summarize the immune-related adverse events (irAEs) profile observed in clinical trials of SCLC immunotherapy.
- To explore the unique features of SCLC immunotherapy-related irAEs compared to other malignancies.
- To provide guidance for the appropriate clinical application of immunotherapy in SCLC.
Main Methods:
- Review of clinical trial data for atezolizumab and durvalumab in SCLC.
- Analysis of reported immune-related adverse events (irAEs).
- Comparative analysis of irAEs in SCLC versus other cancers.
Main Results:
- Atezolizumab and durvalumab have demonstrated survival benefits in SCLC patients.
- Immunotherapy in SCLC is associated with specific irAEs, which can range from mild to severe.
- Severe irAEs, including myocarditis and pneumonitis, can be life-threatening.
Conclusions:
- Immunotherapy represents a significant advancement in SCLC treatment, improving patient survival.
- Understanding and managing immunotherapy-induced irAEs is critical for safe and effective clinical use.
- Further research into irAEs management tailored to SCLC is warranted.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...